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Abstract: Early-stage pancreatic cancer remains challenging to detect, leading to a poor five-year
patient survival rate. This obstacle necessitates the development of early detection approaches
based on novel technologies and materials. In this work, the presence of a specific pancreatic
cancer-derived miRNA (pre-miR-132) is detected using the fluorescence properties of biocompatible
nitrogen-doped graphene quantum dots (NGQDs) synthesized using a bottom-up approach from
a single glucosamine precursor. The sensor platform is comprised of slightly positively charged
(1.14 ± 0.36 mV) NGQDs bound via π − π stacking and/or electrostatic interactions to the negatively
charged (−22.4 ± 6.00 mV) bait ssDNA; together, they form a complex with a 20 nm average
size. The NGQDs’ fluorescence distinguishes specific single-stranded DNA sequences due to bait–
target complementarity, discriminating them from random control sequences with sensitivity in
the micromolar range. Furthermore, this targetability can also detect the stem and loop portions
of pre-miR-132, adding to the practicality of the biosensor. This non-invasive approach allows
cancer-specific miRNA detection to facilitate early diagnosis of various forms of cancer.
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1. Introduction
As the second leading cause of death in the United States, cancer will continue to
threaten human health in the coming decades [1]. Even with the advances in cancer
therapeutics, timely diagnosis is one of the best methods of averting cancer mortality [2].
Developing effective early cancer detection strategies is critical, as cancer is largely asymptomatic until its later stages. Patient prognoses can be improved with preemptive screening
methods, limiting the use of therapeutic cancer treatments and palliative care. Initiatives
for early detection of some common types of cancer already exist within the National
Breast and Cervical Cancer Early Detection Programs. However, despite pancreatic cancer
being the fourth leading cause of cancer-related deaths in the United States, there is neither
a widely adopted screening procedure nor a unified non-invasive test for its diagnosis [3].
Historically, over half of pancreatic cancer diagnoses occur at advanced stages, resulting
in a low 3% 5-year survival rate [3]. Due to the organ’s location deep inside the body,
physical examinations rarely reveal pancreatic tumors, as they often do for other forms of
cancer such as breast, cervical, and lung cancers [4–7]. To effectively detect and diagnose
pancreatic cancer, a combination of procedures that include CT scans, MRIs, endoscopic
ultrasounds, blood tests, and biopsies is used [4]. Designing a single, accurate, and less
invasive testing protocol will enable patients to be diagnosed at earlier stages of pancreatic
cancer with better prognoses. Furthermore, segments of the population including the
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underserved and elderly often lack access to appropriate diagnostic measures, contributing
to poorer health outcomes [8,9]. This barrier to effective care highlights the need for early
diagnostics that do not involve complex, undesirable, or costly procedures. One promising
new avenue can be provided by the detection of cancer-specific microRNA (miRNA).
miRNAs are single-stranded, short (19 to 25 nucleotides) non-coding RNA fragments
that play a critical role in regulating gene expression [10,11]. These molecules are transcribed from DNA and later processed into mature miRNAs that bind to closely matching
messenger RNA (mRNA) sequences. This interaction marks the mRNA for degradation
and represses translation [12]. Overexpressed miRNAs also tend to undergo exocytosis and
endocytosis to surrounding cells and dysregulate mRNA function [13]. As many tumors
leak miRNAs into the bloodstream, miRNAs can serve as potential biomarkers for the
disease [13,14]. Specifically in pancreatic cancer, miRNAs, including miR-34, miR-96, and
miR-143, are downregulated, while others, such as miR-132, miR-301a, and miR-454, are
upregulated [15,16]. From the list of targetable miRNAs, miR-132 is particularly interesting as studies have shown that its function in pancreatic cancer is to target the tumor
suppressor Rb1 mRNA, which promotes cancer tumor growth when inactivated [16]. Furthermore, Khan et al. have demonstrated that, when miR-132 is inhibited, the growth of
the tumor slows [15]. Thus, miR-132 appears to be a promising biomarker for detecting
pancreatic cancer.
An appropriate diagnostic strategy must be selected to conform to potential targets
for detection. miRNAs are commonly detected in biofluids, such as serum, urine, and
peritoneal fluid [10]. However, due to the low abundance of miRNAs in these biofluids [17],
miRNA detection relies on traditional diagnostic tools, such as polymerase chain reaction
(PCR) [18], RNA blotting [19], electrochemistry [20], in situ hybridization [21], and miRNA
microarray technologies [22]. Although these assays enable detection in the attomolar and
femtomolar ranges, they require additional isolation of miRNAs during purification and
amplification steps, leading to false-positive results. These diagnostic technologies are also
limited due to the cost of instrumentation and trained personnel required to perform the
experiments [17]. Furthermore, routine in-person medical visits needed for screening are
hindered due to the low accessibility of hospitals and clinics in remote locations, conflict
with work-related schedules, and public health crises, such as the delayed cancer screenings
occurring during the SARS-CoV-2 pandemic [23]. To alleviate such diagnostic constraints
and ultimately provide efficient, low-cost, and accessible point-of-care cancer detection, we
turn to the advances of nanotechnology in biosensing.
Graphene quantum dots (GQDs) have recently attracted attention in the nanotechnology scientific community due to their small average size of 3–5 nm and large surface-tovolume ratio [24–26], enabling greater interaction with biological analytes. Unlike their
predecessor, graphene, GQDs exhibit photoluminescence (fluorescence) in the visible and, at
times, near-infrared, which can be used as a beacon for the detection of biomolecules [27,28].
Fluorescence emission in the visible can originate from GQDs’ size-dependent quantum
confinement effect or electronically localized regions on sp2 graphitic carbon surrounded
by functional groups. Near-infrared emission can arise from smaller confined electronic
environments at the functional groups or surface defect states [24,25,29,30]. Partially derivatized graphitic GQD surface provides yet another advantage. While functional groups
enable covalent attachment of analytic tools by chemical binding [31–33], sp2 hybridized
regions on the GQDs’ surface enable the loading of aromatic molecules, such as drugs and
nucleic acids, via π − π stacking [34–36]. This non-covalent route allows the formation
of complex nano-biostructures without the need for organic reactions, often involving
toxic chemicals [36,37]. Functional groups left intact, on the other hand, render GQDs
water-soluble, which is also an important advantage for biomedical applications. Our
previous work was focused on developing photostable and highly biocompatible GQDs
as prospective imaging agents and therapeutic delivery vehicles [31,38]. However, GQDs’
fluorescence can also be utilized as a sensing tool. High (over 60% [25]) quantum yield
emission in the visible with their photostability ensures intense signal from GQD-based
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sensors and allows for long accumulation times, pushing sensing limits to lower doses.
Furthermore, near-infrared emissions capable of penetrating layers of biological tissue may
further render GQDs as a basis for implantable sensors. Such nanomaterials, simple and
inexpensive in production [25], can become a building block of the sensing technology,
addressing the aforementioned critical need in early cancer detection.
In this work, biocompatible and biodegradable nitrogen-doped GQDs (NGQDs) [39]
serve as the basis of a simple optical cancer miRNA sensor. These NGQDs are noncovalently bound to bait ssDNA strands that are used as detection probes for miRNA-132
overexpressed in pancreatic cancer. Using short oligonucleotides non-covalently bound to
GQDs is advantageous compared to employing larger sequences due to faster and tighter
adsorption onto the graphitic platform, as demonstrated with graphene and graphene
oxide [40]. The presence of nitrogen dopants in GQDs not only aids with the additional
electrostatic complexation with negatively charged oligonucleotides, but also contributes
to passivating GQDs’ surface defects that affect their fluorescence [39]. To date, no works
utilize the intrinsic GQD or carbon dot fluorescence in miRNA sensing. More often, GQDs
and carbon dots are used as intermediary donors for FRET-based fluorescence mechanisms
with fluorescent dyes [41–43]. However, these dyes may photobleach and are often not
suitable for in vivo applications due to their toxicity [30]. Unlike more elaborate synthetic
approaches, the NGQD-based detection system used in this work does not use chemical
agents other than a single precursor material for NGQD synthesis, which minimizes
potential toxicity, cost, and design complexity [37]. The detection system relies solely
on non-covalent complexation of NGQDs and ssDNA bait as well as intrinsic NGQD
fluorescence to detect pancreatic cancer-generated miRNA-132. Such minimization of
structural and functional complexity is expected to yield the desired simplistic low-cost
pancreatic cancer sensor architecture. In this work, we design an NGQD-based sensor
to assess its feasibility in distinguishing between single-stranded oligos and detecting
fragments of miRNA in pancreatic cancer patients versus non-target genes.
2. Materials and Methods
2.1. Synthesis of Nitrogen-Doped Graphene Quantum Dots (NGQDs)
An amount of 4 g of Glucosamine-HCl (346299, Sigma Aldrich, St. Louis, MO, USA)
was mixed with 250 mL of deionized water and treated in the microwave oven (HBP90D23AP-ST, Hamilton Beach, Southern Pines, NC, USA) for 1 h at a power of 270 W. The
suspension, cooled to room temperature, was dialyzed (0.5–1 kDa, Spectrum Chemical Mfg.
Corp., New Brunswick, NJ, USA) in deionized water for 2 h with 30 min water changes
to remove unreacted precursor material. The product was further freeze-dried (VirTis
Freezemobile, 25ES, SP Scientific, Warminster, PA, USA) for storage and further dilution to
working concentrations.
2.2. Complexation of NGQDs and ssDNA
DNA solution was prepared by mixing 1X TBE (10 mM Tris pH 8, 0.5 M EDTA) buffer
with powdered BSP ssDNA (AAG CAA TCA CCA AAA TGA AGA CT, 50 to 30 ) (IDT
DNA, Coralville, IA, USA). NGQDs and ssDNA in solution were vortexed for 10 s to
facilitate non-covalent complexation without damaging ssDNA through harsher ultrasonic
processing. The final concentrations of 1 mg/mL for NGQDs and 27.4 µM for ssDNA were
achieved in this process.
2.3. Materials Characterization
Fourier Transform Infrared Spectroscopy (FTIR, Thermo Nicolet Nexus, 670, Madison,
WI, USA) was used to assess the functional groups present in NGQDs, with measurements
performed in the attenuated total reflectance (ATR) mode. The Zeta potential measurement
function from the NanoBrook ZetaPALS instrument (Brookhaven Instrument Corporation,
NanoBrook, Holtville, NY, USA) was used to evaluate the net charge of NGQDs/ssDNA in
an aqueous solution before and after the complexation. Transmission electron microscopy
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(TEM, JEOL JEM-2100, Peabody, MA, USA) with energy dispersive x-ray analysis (EDS,
JEOL, Peabody, MA, USA) was further used to determine NGQDs/ssDNA complexation
through their morphology and atomic percentages. Samples were prepared on a carboncoated 200 mesh copper grid (Electron Microscopy Sciences, CF300-CU, Haltfield, PA, USA)
by depositing freeze-dried NGQDs/ssDNA directly onto the grid. Prior to material characterization evaluating the complexation of NGQDs with ssDNA, the sample underwent
centrifugal filtration (10 kDa, Southwest Science, HighSpeed™ Microcentrifuge, Roebling,
NJ, USA) at 10,000× g for 10 min to remove unbound materials. Fluorescence spectral
characterization was performed with the Horiba Scientific SPEX NanoLog spectrofluorometer (Nanolog, HORIBA Scientific, Edison, NJ, USA) to assess the oligonucleotide sensing
capability of the NGQD/ssDNA complex. Visible fluorescence of the samples was acquired
with an excitation wavelength of 400 nm and emission measured in a range of 430 to 650 nm.
Subsequent spectral and statistical (t-test) analyses were performed in Origin software
(OriginLab Corporation, OriginPro 2021b, Northampton, MA, USA).
2.4. Fluorescence Test to Assess ssDNA Binding onto the NGQD Platform along with the
Hybridization of Complementary, Random, and Pre-miR-132
To facilitate the hybridization of bait ssDNA onto the NGQD platform to its complementary (AGT CTT CAT TTT GGT GAT TGC TT, 50 to 30 ) and random (TCC ATT TGG
TTA ATT CGT GTA TC, 50 to 30 ) sequences, NGQDs/ssDNA and the target sequence were
annealed at 62.3 ◦ C for 10 min. Similarly, for the hybridization of loop ssDNA132L (TCC
AGT TCC CAC, 50 to 30 ) and stem ssDNA132S (CGA CCA TGG CTG TAG ACT GTT A,
50 to 30 ) bait sequences to the complementary loop (C132L, GTG GGA ACT GGA, 50 to 30 )
and stem (C132S, TAA CAG TCT ACA GCC ATG GTC G, 50 to 30 ) ssDNA strands, samples
were annealed to 47.2 and 64.8 ◦ C for 10 min, respectively. Lastly, for the hybridization
of the pre-miR-132 (miR-132) strand (GAU UGU UAC UGU GGG AAC UGG AGG UAA
CAG UC, 50 to 30 ), annealing temperatures of 47.2 and 64.8 ◦ C were used respective to
the C132L and C132S bait sequences for 10 min. ssDNA and pre-miR-132 strands were
obtained from IDT DNA, Coralville, IA, USA. Sample were annealed using a thermocyler
(2720 Thermal Cycler, Applied Biosystems, Waltham, MA, USA).
3. Results
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In this work, we assembled and tested a pancreatic cancer miRNA sensor based
on several components: NGQDs acting as a sensing moiety and bait ssDNA132 that is
complementary to the loop part of the pre-miRNA-132 as well as the miRNA duplex
region highlighted in pink in Figure 1. The exposed loop on the right is a quasi-singlestranded region where 12 nucleotides (GTG GGA ACT GGA, 50 to 30 ) have the potential for
hybridization. Additionally, a double-stranded 22 nucleotide sequence (TAA CAG TCT
ACA GCC ATG GTC G, 50 to 30 ) shown in pink can be opened after dehybridization in
the cell’s cytoplasm, which becomes available for binding and, thus, detection. To assess
the feasibility of this sensing mechanism, we first performed the detection of several
ssDNA strands.
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To synthesize NGQDs, a bottom-up synthetic approach was used. During the one-step
microwave-assisted synthesis, glucosamine molecules undergo a dehydration reaction
facilitated by their carboxylic groups. This reaction leads to the polymerization of the
precursor and origination of the nucleation centers that ultimately form NGQDs [44]. This
simple and affordable synthetic procedure is of interest as it uses biodegradable precursors
as the starting material and is free from toxic chemicals typically seen in the complex
organic synthesis of nanomaterials. Prior to assembling the pancreatic miRNA sensor,
two different bait ssDNAs were used to prove the complexation between ssDNA and
the NGQD platform. Indirect assessments of bait NGQDs/ssDNA binding were performed using Zeta potential, transmission electron microscopy (TEM), and high-resolution
TEM (HRTEM).
The complexation of NGQDs with ssDNA was performed via co-incubation of these
nanostructures, allowing for the adsorption of the nucleotides onto the NGQDs’ graphitic
platform, in part via π − π stacking. Post-incubation filtration was used to remove uncomplexed initial materials. This interaction was aided by an electrostatic attraction of
the negatively charged phosphate backbone of the bait ssDNA and positively charged
amine groups of NGQDs apparent in the FTIR spectra (Figure S1). Zeta potential measurements allowed the assessment of the complexation through the change in net electric
charge (Figure S2). With a Zeta potential of 1.14 ± 0.36 mV, NGQDs were incubated with
negatively charged bait ssDNA with a Zeta potential of −22.4 ± 6.00 mV. The resulting
Zeta potential was −1.48 ± 0.76 mV due to the adsorption of the ssDNA onto the NGQD
platform. In addition to the Zeta potential, TEM with HRTEM analysis supported the
complexation of NGQDs and ssDNA.
As reported in our previous work [25], NGQDs alone have an average size of 3–5 nm
(Figure 2a). Their crystallinity was verified by HRTEM scans (Figure S3), showing an inplane lattice spacing of 0.22 nm indicative of graphene. Upon complexation with ssDNA,
a substantial size increase and some agglomeration was observed (Figure 2b). Moreover,
EDS showed the atomic percentages of NGQDs/ssDNA being 82.9% carbon, 4.6% nitrogen,
11.7% oxygen, and 0.73% phosphorus (Figure 2c). The presence of phosphorus, which is
not a component of NGQDs, was indicative of ssDNA. At the same time, a low percentage
of oxygen indicated that the NGQDs’ surface was not fully covered with functional groups,
which allowed for non-covalent binding of ssDNA onto the NGQD graphitic platform.
In this manuscript, the fluorescence of NGQDs was utilized as a sensing mechanism.
Thus, to further assess the interaction between NGQDs and ssDNA, the fluorescence
emission originating from the NGQDs/ssDNA (AAG CAA TCA CCA AAA TGA AGA CT,
50 to 30 ) sensor was compared to that of the NGQDs alone (Figure 3).
A substantial change in spectral intensity upon co-incubation of NGQDs and ssDNA
served as an indicator of their complexation. This complexation is supported by the
works of Jeong et al., which demonstrated the successful binding of ssDNA with GQDs
of lower oxidation levels, resulting in an altered fluorescence response [36]. The increase
in fluorescence intensity upon complexation may result from a charge transfer between
ssDNA and the NGQD platform as well as the change in the dielectric environment of
NGQDs. Next, the potential of the NGQDs/ssDNA complex for nucleic acid-sensing was
analyzed with several tests. The first test assessed the sensor response to the complementary
versus random strands, corresponding to dsDNA formation or incomplete binding. It
was imperative that a specifically different response be observed with complementary
ssDNA strands, as it would indicate the specificity of the sensor and that the device
was not merely displaying the result of a higher total ssDNA concentration. The second
assessment evaluated the minimum detection capability of the platform. Although the
exact concentration of miRNAs in biofluids is not available for pancreatic cancer patients,
the experiment aimed to have a high level of sensitivity.
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To assess the discrimination between complementary and random ssDNA along with
the minimum threshold capability of the NGQDs-based sensor, random and complementary
ssDNAs were added to NGQDs/ssDNA sensor. While keeping NGQD concentrations
at biocompatible 1 mg/mL [39] and bait ssDNA at 27.4 µM (0.2 mg/mL), the amount of
Materials 2022, 15, x FOR PEER REVIEW
of 13
random or complementary ssDNA strands was varied, generating concentration6ratios
from 1:0.01 up to 1:4 (Figure 4).
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In this manuscript, the fluorescence of NGQDs was utilized as a sensing mechanism.
Thus, to further assess the interaction between NGQDs and ssDNA, the fluorescence
emission originating from the NGQDs/ssDNA (AAG CAA TCA CCA AAA TGA AGA
CT, 5′ to 3′) sensor was compared to that of the NGQDs alone (Figure 3).
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A substantial change in spectral intensity upon co-incubation of NGQDs and ssDNA
served as an indicator of their complexation. This complexation is supported by the works
of Jeong et al., which demonstrated the successful binding of ssDNA with GQDs of lower
oxidation levels, resulting in an altered fluorescence response [36]. The increase in fluorescence intensity upon complexation may result from a charge transfer between ssDNA
and the NGQD platform as well as the change in the dielectric environment of NGQDs.
Next, the potential of the NGQDs/ssDNA complex for nucleic acid-sensing was analyzed
with several tests. The first test assessed the sensor response to the complementary versus
random strands, corresponding to dsDNA formation or incomplete binding. It was imperative that a specifically different response be observed with complementary ssDNA
strands, as it would indicate the specificity of the sensor and that the device was not
merely displaying the result of a higher total ssDNA concentration. The second assessment evaluated the minimum detection capability of the platform. Although the exact
concentration of miRNAs in biofluids is not available for pancreatic cancer patients, the
experiment aimed to have a high level of sensitivity.
To assess the discrimination between complementary and random ssDNA along
with the minimum threshold capability of the NGQDs-based sensor, random and complementary ssDNAs were added to NGQDs/ssDNA sensor. While keeping NGQD concentrations at biocompatible 1 mg/mL [39] and bait ssDNA at 27.4 µ M (0.2 mg/mL), the
amount of random or complementary ssDNA strands was varied, generating concentration ratios from 1:0.01 up to 1:4 (Figure 4).
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Fluorescence of NGQDs after the complexation of those with a bait ssDNA experienced a change in intensity—either an increase or a decrease (Figure 4a,b). This fluorescence change was due to the interaction of NGQDs and bait ssDNA only. Although it was
not systematic, as the one arising from the complementary interaction of the bait/target
genes, this fluorescence increase/decrease served to indicate the change in the electronic
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Fluorescence of NGQDs after the complexation of those with a bait ssDNA experienced a change in intensity—either an increase or a decrease (Figure 4a,b). This fluorescence
change was due to the interaction of NGQDs and bait ssDNA only. Although it was not systematic, as the one arising from the complementary interaction of the bait/target genes, this
fluorescence increase/decrease served to indicate the change in the electronic environment
of the NGQDs after bait ssDNA attachment. However, further binding of the target strand
to the sensor driven by gene complementarity was a more systematic event and caused
a monotonic dose-dependent fluorescence response (Figure 4a). Small variations from
this trend can arise from more or less energetically favorable gene conformations on the
NGQD surface. For example, the 1:0.25 ratio appeared to provide somewhat more efficient
complexation than its neighboring concentrations, likely due to the more energetically
favorable conformation of the complexed sensor and ssDNA species at this ratio. This
trend is not yet a signal of dsDNA formation. However, when a random ssDNA strand was
added to the sensor in an aqueous suspension, the dose–response also appeared random
(Figure 4b). The initial intensity increase can be contributed to binding more ssDNA strands
to the NGQDs, but after the 1:0.1 concentration ratio, the integral fluorescence intensity
behavior randomized due to the apparent absence of complementary interaction of the
bait sequence on the NGQDs and the one in suspension. When put in this context, the
monotonic increase in the sensor fluorescence for the complementary sequence can be
interpreted as a result of the hybridization of the bait and target strands on the NGQD
surface. Since a detectable difference in intensity occurred for all concentrations tested,
a micromolar (2.74 µM) sensitivity can be considered. Due to the scope of this work aiming
to discriminate complementary strand form non-specific random gene analyte, one random
ssDNA was tested. However, based on the randomized response observed, we expected
a similar non-specific effect in the absence of a complementary interaction.
After examining the sensing properties of the platform, tests aimed to assess the detection of specific miRNA were performed. At first, ssDNA132 was now utilized as a bait,
complementary to the target pre-miRNA. Pre-miR-132 (Figure 1) is overexpressed in pancreatic cancer patients and has a single-stranded region on its loop alongside a microRNA
duplex (stem) that is dehybridized in the cell’s cytoplasm. To test the detection of each part
of the target separately, we first tested two target ssDNAs corresponding to the aforementioned miRNA regions. Accordingly, two bait sequences were used, complementary to the
target ssDNA representing the loop (ssDNA132L) and stem (ssDNA132S) of pre-miR-132.
This test helped validate the ability to hybridize these targets with the sensor prior to
testing the full RNA version. A 1:1 concentration ratio of the bait ssDNA132 to the target
complementary strands was used as it yielded the greatest NGQDs’ fluorescence difference
when targeting the complementary and random sequences (Figure 4).
While a fluorescence increase was observed for both stem and loop targets (Figure 5),
indicating a possibility for detection, the responses were minimal and not statistically significant. The fluorescence increase trend in Figure 4a suggests that the sensors were functional
for these sequences but not substantially deterministic for utilized concentrations. To assess
the sensing potential of the stem and loop on the actual miRNA, NGQD/ssDNA132S and
NGQD/ssDNA132L sensors were further subjected to the pre-miRNA-132 (miR-132) at
a 1:1 ratio.
Interestingly, a greater increase in fluorescence intensity was observed for both loop
and stem sensors, detecting the actual miR-132 rather than its smaller DNA counterparts.
This difference is potentially attributed to the charge transfer between NGQDs and a larger
ribonucleic acid, which enables deterministic detection of both the loop and stem of the
target miRNA at a concentration of 27.4 µM. The following results suggest that miR-132
can be detected using the proposed NGQD platform, which is the objective of this work.
To define the stability of the sensor, the fluorescence of NGQDs/ssDNA132S without and
with the complexation with miR-132 were measured within 25 h (Figure S4). A similar
decrease in intensities was observed within the first 3 h for both NGQDs/ssDNA132S
and NGQDs/ssDNA132S + miR-132. However, within the next hours, their fluores-
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cence intensities remained stable. This trend indicates that miR-132 is not detached from
NGQDs/ssDNA132 to alter the fluorescence of NGQDs/ssDNA132S + miR-132, and the
After examining the sensing properties of the platform, tests aimed to assess the desensor continues to successfully detect the presence of the analyte. Furthermore, to detertection of specific miRNA were performed. At first, ssDNA132 was now utilized as a bait,
mine the sensitivity of the NGQDs/ssDNA132 sensor in detecting miR-132, the stem and
complementary to the target pre-miRNA. Pre-miR-132 (Figure 1) is overexpressed in panloop sensors were treated with a range of miR-132 concentrations down to 0.274 µM for
creatic cancer patients and has a single-stranded region on its loop alongside a microRNA
a 1:0.01 ratio between the bait ssDNA132 and miR-132 (Figure 6).
duplex (stem) that is dehybridized in the cell’s cytoplasm. To test the detection of each
In the chosen range, both sensors generally showed a monotonic signal increase with
part of the target separately, we first tested two target ssDNAs corresponding to the aforegreater analyte concentrations. Intensity fluctuations at low concentrations between the
mentioned miRNA regions. Accordingly, two bait sequences were used, complementary
1:0.01 and 1:0.1 ratios for the loop sensor were generally within the error bars and can occur
to the target ssDNA representing the loop (ssDNA132L) and stem (ssDNA132S) of preif lower ratios provide slightly more energetically favorable configuration. The biosensor
miR-132. This test helped validate the ability to hybridize these targets with the sensor
targeting the stem of miR-132 had an initial statistically significant response (p < 0.05) at
prior to testing the full RNA version. A 1:1 concentration ratio of the bait ssDNA132 to the
the 1:0.1 concentration ratio, corresponding to the 2.74 µM miR-132 concentration. On
target complementary strands was used as it yielded the greatest NGQDs’ fluorescence
the other hand, for the biosensor targeting the loop of miR-132, a statistically significant
difference when targeting the complementary and random sequences (Figure 4).
response (p < 0.05) was initially observed at 1:0.25, corresponding to the 6.85 µM miR-132
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stem anddetection
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the minimal
sensitivity
of the NGQD/ssDNA132
remains insigthe
nificant.
The
fluorescence
increase
trend
in
Figure
4a
suggests
that
the
sensors
were
funcmicromolar range, which is suitable for diagnosing the onset and progression
of cancer
tionalexfor
these
sequences
not substantially
deterministic
for utilized
concentrations.
from
vivo
samples,
such but
as cells
and tissues [18,45–47].
However,
most importantly,
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Figure5.5. The
The detection
detection of loop (a) and stem (b)
Figure
(b) of
of pre-miR-132
pre-miR-132and
andits
itsssDNA
ssDNAversion.
version.Fluorescence
Fluorescence
spectra
of
NGQDs
(grey),
NGQDs
complexed
with
the
bait
for
either
the
loop
or
spectra of NGQDs (grey), NGQDs complexed with the bait for either the loop or stem
stemssDNA132L/S
ssDNA132L/S
(red), NGQDs complexed with the loop or stem bait (ssDNA132L/S) mixed with their respective
(red), NGQDs complexed with the loop or stem bait (ssDNA132L/S) mixed with their respective
complementary ssDNA strands (C132L/S) (orange) or miR-132 (green). Corresponding integrated
complementary ssDNA strands (C132L/S) (orange) or miR-132 (green). Corresponding integrated
spectral intensities are shown as bar plots.
spectral intensities are shown as bar plots.

Interestingly, a greater increase in fluorescence intensity was observed for both loop
and stem sensors, detecting the actual miR-132 rather than its smaller DNA counterparts.
This difference is potentially attributed to the charge transfer between NGQDs and a
larger ribonucleic acid, which enables deterministic detection of both the loop and stem
of the target miRNA at a concentration of 27.4 µ M. The following results suggest that miR132 can be detected using the proposed NGQD platform, which is the objective of this
work. To define the stability of the sensor, the fluorescence of NGQDs/ssDNA132S
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NGQDs/ssDNA132S and NGQDs/ssDNA132S + miR-132. However, within the next
hours, their fluorescence intensities remained stable. This trend indicates that miR-132 is
not detached from NGQDs/ssDNA132 to alter the fluorescence of NGQDs/ssDNA132S +
miR-132, and the sensor continues to successfully detect the presence of the analyte. Furthermore, to determine the sensitivity of the NGQDs/ssDNA132 sensor in detecting miR10 of 13
132, the stem and loop sensors were treated with a range of miR-132 concentrations down
to 0.274 µ M for a 1:0.01 ratio between the bait ssDNA132 and miR-132 (Figure 6).

Figure6.6. Threshold
Threshold fluorescence
fluorescence sensitivity
sensitivity assessment
Figure
assessment of
of NGQDs/ssDNA132
NGQDs/ssDNA132sensor
sensorfor
formiR-132.
miR-132.
Fluorescence of
of (a)
(a) NGQDs/ssDNA132S
NGQDs/ssDNA132S and
Fluorescence
and (b)
(b) NGQDs/ssDNA132L
NGQDs/ssDNA132Lmixed
mixedwith
withmiR-132
miR-132atatthe
the
concentration ratios of 1:0.01 (orange), 1:0.1 (yellow), 1:0.25 (green), 1:0.5 (teal), 1:1 (light blue). Corconcentration ratios of 1:0.01 (orange), 1:0.1 (yellow), 1:0.25 (green), 1:0.5 (teal), 1:1 (light blue).
responding integrated spectral intensities shown as bar plots.
Corresponding integrated spectral intensities shown as bar plots.

In the chosen range, both sensors generally showed a monotonic signal increase with
4. Conclusions
greater analyte concentrations. Intensity fluctuations at low concentrations between the
In this work, we developed a low-cost biocompatible and nitrogen-doped graphene
1:0.01 and 1:0.1 ratios for the loop sensor were generally within the error bars and can
quantum dots (NGQDs) sensor for pancreatic cancer miRNA (miRNA-132). The sensing
occur if lower ratios provide slightly more energetically favorable configuration. The biomechanism is based on the variation of NGQDs’ intrinsic fluorescence intensity with
sensor targeting the stem of miR-132 had an initial statistically significant response (p <
the complementary binding of the target gene to the bait ssDNA on the NGQD surface.
0.05) at the 1:0.1 concentration ratio, corresponding to the 2.74 µ M miR-132 concentration.
NGQDs are synthesized via a simple one-step hydrothermal microwave-assisted process
On the other hand, for the biosensor targeting the loop of miR-132, a statistically signififrom a single biocompatible glucosamine precursor, which makes them water-soluble and
cant response (p < 0.05) was initially observed at 1:0.25, corresponding to the 6.85 µ M miRbiocompatible at concentrations over 1 mg/mL. Zeta potential measurements suggest
132 concentration. These results suggest the initial and progressive detection of the anathat the detection platform, NGQD, is positively charged (1.14 ± 0.36 mV) and the bait
lyte. At the same time, the minimal sensitivity of the NGQD/ssDNA132 sensor remains in
ssDNA sensing sequence is negatively charged (−22.4 ± 6.00 mV), where ssDNA binds
the micromolar range, which is suitable for diagnosing the onset and progression of canelectrostatically and via π − π stacking onto the NGQD’s graphitic surface. Binding with
cer from ex vivo samples, such as cells and tissues [18,45–47]. However, most importantly,
the bait ssDNA sequence altered the fluorescence intensity of the NGQD, likely due to
this work verifies the capability of using GQDs’ intrinsic properties for miRNA detection
charge transfer from ssDNA as it formed 20 nm complexes. The specificity and sensitivity
and sets the benchmark to advance the detection limit towards the attomolar range, which
of the resulting NGQDs/ssDNA sensor were tested against ssDNA and miRNA targets.
is suitable for sensing in biofluids [48].
The sensor showed a specific ssDNA dose-dependent response only to the complementary
target, with minimal sensitivity in the micromolar range. While the platform also showed
some response to the ssDNA sequences mimicking the loop and stem single-stranded parts
of the miRNA, its response to the actual miRNA was more dramatic. Both sensors for the
stem and loop parts of the miRNA-132 exhibited dose-dependence at the corresponding
minimal concentrations of 2.74 and 6.85 µM. This detection capability warrants the potential
for ex vivo cancer miRNA detection with the advantages of being low-cost, simple, and noninvasive. This developed biosensor addresses multiple critical needs of cancer diagnostics
and sets the groundwork for further development of attomolar gene concentration sensing
in vivo.
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Supplementary Materials: The following supporting information can be downloaded at: https://www.
mdpi.com/article/10.3390/ma15165760/s1. Figure S1: FTIR spectrum of NGQDs; Figure S2: Zeta
potential of NGQDs (orange), ssDNA (green), NGQDs/ssDNA (purple) with the corresponding
values of 1.14 ± 0.36, −22.4 ± 6.00, and −1.48 ± 0.76 mV; Figure S3: HRTEM and FFT of (a,b)
NGQDs and (c,d) NGQDs/ssDNA. Figure S4: Stability test of NGQDs/ssDNA132S (red) and
NGQDs/ssDNA132S+miR-132 (green).
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